ATE353921T1 - Chimäre polypeptide, verfahren zur herstellung und verwendung dafür - Google Patents

Chimäre polypeptide, verfahren zur herstellung und verwendung dafür

Info

Publication number
ATE353921T1
ATE353921T1 AT00948017T AT00948017T ATE353921T1 AT E353921 T1 ATE353921 T1 AT E353921T1 AT 00948017 T AT00948017 T AT 00948017T AT 00948017 T AT00948017 T AT 00948017T AT E353921 T1 ATE353921 T1 AT E353921T1
Authority
AT
Austria
Prior art keywords
production
chimeric polypeptides
chimeric
polypeptides
Prior art date
Application number
AT00948017T
Other languages
English (en)
Inventor
Hauke Lilie
Susanne Richter
Rainer Rudolph
Kay-Gunnar Stubenrauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE353921T1 publication Critical patent/ATE353921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
AT00948017T 1999-08-02 2000-07-31 Chimäre polypeptide, verfahren zur herstellung und verwendung dafür ATE353921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115022A EP1074563A1 (de) 1999-08-02 1999-08-02 Erhöhte Bildung von Chimären Polypeptiden durch Ausbildung von Dimeren mittels elektrostatischen wechselwirkungen und Disulfidbindungen sowie Verfahren zur Herstellung und Anwendungen

Publications (1)

Publication Number Publication Date
ATE353921T1 true ATE353921T1 (de) 2007-03-15

Family

ID=8238697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948017T ATE353921T1 (de) 1999-08-02 2000-07-31 Chimäre polypeptide, verfahren zur herstellung und verwendung dafür

Country Status (17)

Country Link
US (1) US6437095B1 (de)
EP (2) EP1074563A1 (de)
JP (1) JP4011914B2 (de)
KR (1) KR100484084B1 (de)
CN (1) CN1184235C (de)
AR (1) AR021448A1 (de)
AT (1) ATE353921T1 (de)
AU (1) AU768645B2 (de)
BR (1) BR0012926A (de)
CA (1) CA2380569C (de)
DE (1) DE60033405T2 (de)
DK (1) DK1206495T3 (de)
ES (1) ES2280231T3 (de)
MX (1) MXPA02001139A (de)
TR (1) TR200200252T2 (de)
WO (1) WO2001009193A1 (de)
ZA (1) ZA200109746B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7550557B2 (en) 2003-08-29 2009-06-23 Louisiana Tech University Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
US7544770B2 (en) * 2003-08-29 2009-06-09 Louisiana Tech Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
AU2004325199B2 (en) * 2004-11-22 2011-09-08 Louisiana Tech University Foundation Method for designing polypeptides for the nanofabrication of thin films, coatings and microcapsules by electrostatic layer-by-layer self assembly.
BRPI0519047A2 (pt) * 2004-12-17 2008-12-23 Koninkl Philips Electronics Nv mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2659269B1 (de) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Erkennung von posttranslational modifiziertem polypeptid durch ein bivalentes bindungsmolekül
CN103384831B (zh) 2010-12-23 2016-02-10 霍夫曼-拉罗奇有限公司 通过二价结合剂来检测多肽二聚体
CN103384681B (zh) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 结合剂
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012107932A1 (en) * 2011-02-11 2012-08-16 Transgene Biotek Ltd. B cell clonal immunotoxin and use thereof
AR086924A1 (es) 2011-06-15 2014-01-29 Hoffmann La Roche Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
BR112014029888A2 (pt) 2012-06-27 2020-05-12 Hoffmann La Roche Métodos de produção de um anticorpo, de determinação de uma combinação de sítios de ligação e de tratamento de um indivíduo com câncer, formulação farmacêutica, anticorpo e uso de um anticorpo
EP3647322B1 (de) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilisierte fibronectinbasierte gerüstmoleküle
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
RS60631B1 (sr) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
EP3224277B1 (de) 2014-11-25 2020-08-26 Bristol-Myers Squibb Company Neuartige pd-l1-bindende polypeptide zur bildgebung
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
PT3233912T (pt) 2014-12-19 2021-08-09 Regenesance B V Antocorpos que se ligam a c6 humano e utilizações destes
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3733698A1 (de) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
EP3583124A1 (de) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antikörper gegen alpha-synuklein und verwendungen davon
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CA3127236A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US20220214340A1 (en) * 2019-04-28 2022-07-07 Leide Biosciences Co., Ltd. Zipper structure that helps the formation of protein dimer and application thereof
EP3999543A1 (de) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Anti-trem-1-antikörper und verwendungen davon
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CN112694527B (zh) * 2020-12-25 2022-09-09 山东睿鹰制药集团有限公司 一种重组人干扰素-κ包涵体的纯化和复性方法
EP4314068A1 (de) 2021-04-02 2024-02-07 The Regents Of The University Of California Antikörper gegen gespaltenes cdcp1 und verwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK132892D0 (da) * 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE69830901T2 (de) * 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen

Also Published As

Publication number Publication date
JP2003506028A (ja) 2003-02-18
KR100484084B1 (ko) 2005-04-20
DE60033405T2 (de) 2007-10-31
EP1206495A1 (de) 2002-05-22
DK1206495T3 (da) 2007-06-11
BR0012926A (pt) 2002-04-30
CN1358198A (zh) 2002-07-10
TR200200252T2 (tr) 2002-05-21
AR021448A1 (es) 2002-07-17
MXPA02001139A (es) 2002-08-20
CA2380569A1 (en) 2001-02-08
JP4011914B2 (ja) 2007-11-21
AU6161000A (en) 2001-02-19
US6437095B1 (en) 2002-08-20
ZA200109746B (en) 2003-03-12
CN1184235C (zh) 2005-01-12
CA2380569C (en) 2008-01-22
KR20020026558A (ko) 2002-04-10
EP1206495B1 (de) 2007-02-14
DE60033405D1 (de) 2007-03-29
AU768645B2 (en) 2003-12-18
WO2001009193A1 (en) 2001-02-08
ES2280231T3 (es) 2007-09-16
EP1074563A1 (de) 2001-02-07

Similar Documents

Publication Publication Date Title
ATE353921T1 (de) Chimäre polypeptide, verfahren zur herstellung und verwendung dafür
DE60018805D1 (de) Oberflächenmodifiziertes anorganisches oxidpulver, verfahren zur herstellung desselben und verwendung desselben
DE69921099D1 (de) Wärmeausdehnbare mikrokapseln, verfahren zur herstellung und verwendung derselben
DE69812341D1 (de) Poröse gesinterte kunststoffprodukte und verfahren zur herstellung
DE60027721D1 (de) Bodenbelag, giessform und verfahren zur herstellung derselben
DE59813187D1 (de) Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
DE69911549D1 (de) Wässrige zusammensetzung, wässrige schneidfluid, verfahren zur herstellung und zur verwendung
DE69916873D1 (de) Piezo tintenstrahltinten und verfahren zur herstellung und verwendung derselben
DE60132554D1 (de) STATORBLECHKöRPER UND VERFAHREN ZUR HERSTELLUNG DESSELBEN
DE60002505D1 (de) Lithium kobaltoxide und verfahren zur herstellung
ATE208628T1 (de) Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon
DE60129589D1 (de) Wabenfilter und verfahren zur herstellung desselben
DE69819015D1 (de) Norbonenpolymer und verfahren zur herstellung
DE69725329D1 (de) Richtungsweisende markierung mit hervortretenden erhebungen und verfahren zur herstellung
DE69901178T2 (de) Nichtgesinterte elektrode und verfahren zur herstellung
DE60045480D1 (de) Druckempfindliches klebeband und verfahren zur herstellung desselben
DE69903631T2 (de) Beschichtungszusammensetzung, verfahren zur herstellung und kratzfeste kunststofflinse
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
DE69812365D1 (de) Enthaarungsmitteln, verfahren zur herstellung sowie ihre verwendung
DE60213444D1 (de) Fluorpolymerlaminate und verfahren zur herstellung derselben
ATE258558T1 (de) Lantibiotikum verwandt mit actagardine, verfahren zur herstellung und verwendung desselben
DE60133124D1 (de) Poröses schallschluckendes material und verfahren zur herstellung desselben
DE69902105D1 (de) Biozides material und verfahren zur dessen herstellung
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE60013541D1 (de) Keramischer stiftheizer mit integrieten anschlusskontakten und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206495

Country of ref document: EP